CoChat

TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children

Open access
Qian, Maoxiang, Cao, Xueyuan, Devidas, Meenakshi, Yang, Wenjian, Cheng, Cheng, Dai, Yunfeng, Carroll, Andrew, Heerema, Nyla A., Zhang, Hui, Moriyama, Takaya, Gastier-Foster, Julie M., Xu, Heng, Raetz, Elizabeth, Larsen, Eric, Winick, Naomi, Bowman, W. Paul, Martin, Paul L., Mardis, Elaine R., Fulton, Robert, Zambetti, Gerard, Borowitz, Michael, Wood, Brent, Nichols, Kim E., Carroll, William L., Pui, Ching-Hon, Mullighan, Charles G., Evans, William E., Hunger, Stephen P., Relling, Mary V., Loh, Mignon L., Yang, Jun J. · 2018 · Journal of Clinical Oncology
Cited by 176

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Purpose: Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods: Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children’s Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results: We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion: Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.75.5215

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 176

Metadata

Authors
Qian, M., Cao, X., Devidas, M., Yang, W., Cheng, C., Dai, Y., Carroll, A., Heerema, N. A., Zhang, H., Moriyama, T., Gastier-Foster, J. M., Xu, H., Raetz, E., Larsen, E., Winick, N., Bowman, W. P., Martin, P. L., Mardis, E. R., Fulton, R., Zambetti, G., Borowitz, M., Wood, B., Nichols, K. E., Carroll, W. L., Pui, C.-H., Mullighan, C. G., Evans, W. E., Hunger, S. P., Relling, M. V., Loh, M. L., & Yang, J. J.
Venue
Journal of Clinical Oncology
Published
2018-02-20
Volume
36
Issue
6
Pages
591-599
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2781535566
Cited by
176
References
12
FWCI
18.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.